HUADONG MEDICINE(SZ:000963) Quan Jing Wang·2026-02-03 10:51Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., has received acceptance for the marketing authorization application of Roflumilast cream (ZORYVE®) 0.05%, aimed at treating mild to moderate atopic dermatitis in children aged 2 to 5, marking a significant milestone in the product's development and enhancing the company's competitive edge in the autoimmune skin treatment sector [1][2]. Product Advantages - ZORYVE® contains Roflumilast, a highly selective non-steroidal phosphodiesterase-4 (PDE4) inhibitor that reduces inflammation by inhibiting the enzyme that increases pro-inflammatory mediators [2]. - The product was developed in collaboration with Arcutis Biotherapeutics, granting Huadong exclusive rights for development, registration, production, and commercialization in Greater China and Southeast Asia [2]. - Atopic dermatitis is a prevalent chronic inflammatory skin condition affecting both children and adults, with significant impacts on quality of life [2]. Market Demand - There are approximately 67 million atopic dermatitis patients in China, indicating a substantial unmet clinical need, particularly for children aged 1 to 7, with a prevalence rate of 12.94% [3]. - The introduction of Roflumilast cream addresses a clear gap in treatment options for children aged 2 to 5, who currently rely on traditional topical corticosteroids and calcineurin inhibitors [3]. - The cream's once-daily dosing regimen enhances treatment adherence, making it a more suitable option for young patients [3]. Strategic Development - Huadong Medicine is systematically introducing a range of Roflumilast products, including higher concentrations for older patients and other skin conditions, to establish a comprehensive presence in the autoimmune skin disease market [4]. - The company is focusing on a dual strategy of "introducing partnerships" and "independent innovation" to build a competitive product pipeline in autoimmune diseases, covering various conditions such as psoriasis and rheumatoid arthritis [5]. - Ongoing collaborations and clinical trials for other products further demonstrate the company's commitment to expanding its portfolio in the autoimmune sector [6]. Strategic Partnerships - In early 2026, Huadong Medicine deepened its strategic partnership with Denmark's MC2 Therapeutics to commercialize the Biomee® series in Greater China, enhancing its position in the topical skin treatment market [7]. - The acceptance of the Roflumilast cream application signifies the company's innovative capabilities and marks a phase of growth in the autoimmune skin disease field [7]. - With multiple differentiated product pipelines, Huadong Medicine aims to strengthen its influence in the multi-billion-dollar autoimmune market in China [7].